Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Radiant Research, Dallas, Texas 75235, USA.
Arthritis & Rheumatology (Impact Factor: 7.87). 09/2006; 54(9):2793-806. DOI: 10.1002/art.22025
Source: PubMed

ABSTRACT In addition, for the first time in a patient population who had an inadequate response to 1 or more anti-TNF agents, an exploratory analysis of radiographic data at 24 weeks demonstrated a trend toward less progression of structural joint damage. The mean increases from baseline in the total Genant-modified Sharp scores, erosion scores, and joint space narrowing scores at 24 weeks in rituximab-treated patients were half those in placebo-treated patients, with the joint space narrowing score reaching statistical significance at week 24. It is important to recognize that this portion of the trial was only 6 months in duration, allowed rescue therapy between weeks 16 and 24 (with 40% of the placebo group and 13% of the rituximab group entering the rescue protocol at or after week 16), and included intravenous and oral steroids for the first 2 weeks in both the placebo and rituximab groups. While glucocorticoids have been shown to reduce the rate of radiographic progression of RA (31), all patients in this trial received glucocorticoids. Therefore, the effects of glucocorticoids on radiographic progression could not be assessed. Additionally, all patients had previously taken anti-TNF agents. Glucocorticoid administration and previous therapy with anti-TNF agents may have affected the ability to detect significant differences in radiographic changes between treatment groups. The effect of rituximab on radiographic progression will be further evaluated in longer-term followup from this study as well as in an additional study.


Available from: Paul Emery, Sep 23, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the safety and efficacy of ocrelizumab (OCR) in Japanese patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX). RA patients with an inadequate response to MTX 6-8 mg/week received an infusion of 50, 200, or 500 mg OCR or placebo on Days 1 and 15 and were observed for 24 weeks. The double-blind period was prematurely terminated because of a possible risk for serious infection from OCR. A total of 152 patients were randomized into the study. The incidence of infection was 37.7% (43/114) in the OCR groups combined, compared to 18.9% (7/37) in the placebo group. Serious infections occurred in 7 patients in the OCR groups combined; there were no serious infections in the placebo group. Among the serious infections, Pneumocystis jirovecii pneumonia occurred in 2 patients in the OCR 200 mg group. The American College of Rheumatology 20% response rates at Week 24 (the primary endpoint) of the OCR 50, 200, and 500 mg groups were 54.1% (p = 0.0080), 55.6% (p = 0.0056), and 47.2% (p = 0.044), respectively, all significantly higher than that of the placebo group (25.0%). These results suggest inappropriate benefit-risk balance of OCR in this patient population. Because rituximab is not approved for treatment of RA in Japan, it will be necessary to investigate safety and efficacy of other anti-B cell therapies in Japanese patients with RA. ( NCT00779220).
    The Journal of Rheumatology 03/2012; 39(3):486-95. DOI:10.3899/jrheum.110994 · 3.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The approval - several years ago - of the first tumour necrosis factor-α (TNF-α) inhibitor for the management of rheumatoid arthritis launched a new era in the therapeutics of rheumatology. Since then an almost cataclysmic discovery of new treatment targets and corresponding biologic agents ensued. Nowadays, the rheumatologist and the rheumatologic patient have the luxury of several immune modulators available to successfully treat the majority of patients with RA or other inflammatory arthritides and conditions. In this review we focus on a discussion of the approved immune modulators/biologic agents available for the treatment of rheumatoid arthritis. We also present an overview of agents under development. For the immune modulators discussed, we describe their mechanism of action and summarise initial data and recent updates on efficacy and safety.
    Best practice & research. Clinical rheumatology 12/2011; 25(6):873-89. DOI:10.1016/j.berh.2011.11.003 · 3.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Significant improvements in the knowledge of cancer biology have permitted the development of new molecular targeted therapies. Meanwhile, a better understanding of the physiology of various non-cancerous diseases has allowed developing these agents in other areas. This review intends to illustrate these perspectives through examples corresponding to different strategies of molecular-targeted therapies : use of a monoclonal antibody binding a receptor (rituximab and rheumatoid arthritis) or a ligand (bevacizumab and age-related macular degeneration), tyrosine kinase inhibitor (imatinib and systemic sclerosis) or inhibitor of cytoplasmic signal transduction pathways (immunosuppressive and antiproliferative effects of mammalian target of rapamycin [mTOR] inhibitors). Clinical results can draw today what could become molecular medicine of tomorrow.
    Bulletin du cancer 10/2012; 99(10):953-962. DOI:10.1684/bdc.2012.1641 · 0.64 Impact Factor